A non-canonical vitamin K cycle is a potent ferroptosis suppressor.
Mishima E, Ito J, Wu Z, Nakamura T, Wahida A, Doll S, Tonnus W, Nepachalovich P, Eggenhofer E, Aldrovandi M, Henkelmann B, Yamada KI, Wanninger J, Zilka O, Sato E, Feederle R, Hass D, Maida A, Mourão ASD, Linkermann A, Geissler EK, Nakagawa K, Abe T, Fedorova M, Proneth B, Pratt DA, Conrad M. · 2022
Read A non-canonical vitamin K cycle is a potent ferroptosis suppressor. by Mishima E, Ito J, Wu Z, Nakamura T, Wahida A, Doll S, Tonnus W, Nepachalovich P, Eggenhofer E, Aldrovandi M, Henkelmann B, Yamada KI, Wanninger J, Zilka O, Sato E, Feederle R, Hass D, Maida A, Mourão ASD, Linkermann A, Geissler EK, Nakagawa K, Abe T, Fedorova M, Proneth B, Pratt DA, Conrad M. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9402432.txt.
Introduction
Mishima and co-authors report that vitamin K can block ferroptosis, a form of cell death driven by iron and lipid damage. Ferroptosis plays a part in organ injury and in some cancers that resist treatment. The team asked what other cell systems guard against it.
They found that the fully reduced forms of vitamin K act as strong radical traps. These forms stop lipid damage before membranes break. An enzyme called FSP1 makes the reduced form from vitamin K. That same step explains how vitamin K works as an antidote to warfarin poisoning. The authors frame this as a non-canonical vitamin K cycle. It sits apart from the known clotting role of the vitamin.
Catalog record
| CREATOR | Mishima E, Ito J, Wu Z, Nakamura T, Wahida A, Doll S, Tonnus W, Nepachalovich P, Eggenhofer E, Aldrovandi M, Henkelmann B, Yamada KI, Wanninger J, Zilka O, Sato E, Feederle R, Hass D, Maida A, Mourão ASD, Linkermann A, Geissler EK, Nakagawa K, Abe T, Fedorova M, Proneth B, Pratt DA, Conrad M. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 80 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A non-canonical vitamin K cycle is a potent ferroptosis suppressor By Eikan Mishima, Junya Ito, Zijun Wu, Toshitaka Nakamura, Adam Wahida, Sebastian Doll, Wulf Tonnus, Palina Nepachalovich, Elke Eggenhofer, Maceler Aldrovandi, Bernhard Henkelmann, Ken-ichi Yamada Published in: Nature DOI: 10.1038/s41586-022-05022-3 ABSTRACT Ferroptosis, a non-apoptotic form of cell death marked by iron-dependent lipid peroxidation1, has a key role in organ injury, degenerative disease and vulnerability of therapy-resistant cancers2. Although substantial progress has been made in understanding the molecular processes relevant to ferroptosis, additional cell-extrinsic and cell-intrinsic processes that determine cell sensitivity toward ferroptosis remain unknown. Here we show that the fully reduced forms of vitamin K—a group of naphthoquinones that includes menaquinone and phylloquinone3—confer a strong anti-ferroptotic function, in addition to the conventional function linked to blood clotting by acting as a cofactor for γ-glutamyl carboxylase. Ferroptosis suppressor protein 1 (FSP1), a NAD(P)H-ubiquinone reductase and the second mainstay of ferroptosis control after glutathione peroxidase-44,5, was found to efficiently reduce vitamin K to its hydroquinone, a potent radical-trapping antioxidant and inhibitor of (phospho)lipid peroxidation. The FSP1-mediated reduction of vitamin K was also responsible for the antidotal effect of vitamin K against warfarin poisoning. It follows that FSP1 is the enzyme mediating warfarin-resistant vitamin K reduction in the canonical vitamin K cycle6. The FSP1-dependent non-canonical vitamin K cycle can act to protect cells against detrimental lipid peroxidation and ferroptosis. MAIN Unrestrained iron-dependent lipid peroxidation is the common downstream cellular event leading to rupture of cellular membranes and ferroptosis7. Cells have evolved a number of highly efficient redox systems that counteract uncontrolled lipid peroxidation, such as selenium-dependent glutathione peroxidase-4 (GPX4), the FSP1-ubiquinone pathway, and the biopterin-dihydrofolate reductase system4,8–12. In addition, cells and tissues harness vitamin E (comprising both tocopherols and tocotrienols), Nature’s premier lipophilic radical-trapping antioxidants13 (RTA), to protect them from overwhelming lipid peroxidation and ferroptosis7. Vitamin E has also been shown to rescue certain tissues, including liver, endothelium, CD8+ T cells and hematopoietic stem cells, from the deleterious consequences induced by the tissue-specific disruption of the key ferroptosis regulator GPX414–16. VITAMIN K IS A POTENT ANTI-FERROPTOTIC COMPOUND To interrogate whether there are other systems besides the aforementioned intrinsic and extrinsic mechanisms that efficiently prevent ferroptosis, we systematically studied a number of naturally available vitamin compounds in mouse embryonic fibroblasts with tamoxifen (TAM)-inducible deletion of Gpx4 (referred to as Pfa1 cells8) (Extended Data Fig. 1a). Notably, besides α-tocopherol (α-TOH), the most biologically active form of vitamin E, only the three forms of vitamin K, phylloquinone, menaquinone-4 (MK4) and menadione, rescued cells from ferroptosis induced by Gpx4 deletion (Fig. 1a,b). Phylloquinone is obtained mostly from leafy green vegetables, and can be converted to MK4 in the body, whereas menadione is a synthetic variant. The anti-ferroptotic activity of vitamin K was not only limited to mouse fibroblasts, as it also prevented ferroptosis in the human cancer cell lines A375 and 786-O that lack GPX4 expression (Fig. 1c and Extended Data Fig. 1b). Phylloquinone, MK4 and menadione also efficiently rescued cells from ferroptosis triggered by well-established ferroptosis inducers17 including a GPX4 inhibitor (1S,3R)-RSL3 (RSL3) in fibrosarcoma HT-1080 cells (Fig. 1d and Supplementary Videos 1 and 2), as well as in other cancer and non-cancer cell lines (Extended Data Fig. 1c,d). In addition, all three vitamin K forms prevented glutamate-induced neuronal ferroptosis, whereas they failed to protect against other types of cell death, except protection of pyroptosis by menadione18 (Extended Data Fig. 1e,f). Phylloquinone and MK4 showed no cellular toxicity up to 100 µM, although high doses of menadione (over 10 µM) showed signs of toxicity, probably owing to the generation of reactive oxygen species, as reported19 (Extended Data Fig. 1g). Menadione, which lacks an aliphatic sidechain, also rescued cells from ferroptosis—albeit with lower efficacy—whereas dimethylmenadione, a redox-inactive form, did not prevent ferroptosis (Extended Data Fig. 1h). This suggests that the quinone head group is a structural requirement for the anti-ferroptotic function.Fig. 1Vitamin K is a potent class of anti-ferroptotic compounds.a, Viability of 4-hydroxytamoxifen (4-OH-TAM)-induced GPX4-KO mouse embryonic fibroblasts (Pfa1 cells) treated with phylloquinone (PK), MK4, menadione (Menad), α-TOH or liproxstatin-1 (Lip1), a well-established ferroptosis inhibitor. b, Lactate dehydrogenase (LDH) release by Pfa1 cells at the indicated time after addition of 4-OH-TAM. Phylloquinone (1 µM), MK4 (1 µM), menadione (3 µM) or Lip1 (0.5 µM). c, Viability of A375 GPX4-KO cells treated with the indicated compound five days after withdrawal of Lip1, which is required to maintain the GPX4-KO cells. d, Left, images of HT-1080 cells treated with RSL3 (0.5 µM) with or without MK4 (3 µM) during live imaging (see also Supplementary Videos 1 and 2). Scale bars, 10 µm. Right, heat map showing the viability of HT-1080 cells co-treated with the indicated compounds and ferroptosis inducers. Phylloquinone (3 µM), MK4 (3 µM), menadione (3 µM) or Lip1 (0.5 µM) were added 1 h before the addition of the inducers. e, Heat map showing relative amounts of oxidized phospholipids in Pfa1 cells treated with RSL3 (0.5 µM) for 8 h. Phylloquinone, MK4 and menadione (3 µM) were added 6 h before the addition of RSL3. oxPE, oxidized phosphatidylethanolamines; oxPC, oxidized phosphatidylcholines. f, Lipid peroxidation evaluated by BODIPY 581/591 C11 staining of Pfa1 cells. RSL3 (–), cells without RSL3 treatment. g, Immunohistochemistry of GPX4 in the liver of TAM-induced hepatocyte-specific GPX4-KO (Alb-creERT2;Gpx4fl/fl) mice and cre− mice after TAM injection. h, Survival rate of Alb-creERT2;Gpx4fl/fl mice fed a diet with low vitamin E at the indicated time of MK4 treatment (200 mg kg−1 day−1, intraperitoneal injection) or vehicle. n = 5 per group. i, Evaluation of liver injury in Alb-creERT2;Gpx4fl/fl mice analysed seven days after TAM injection. Left, immunoblotting for 4-hydroxynonenal (4HNE) and GPX4. Middle, serum levels of alanine transaminase (ALT). Right, images of liver and histology (haematoxylin and eosin staining (HE), TUNEL staining and immunohistochemistry for 4HNE). Scale bars, 5 mm (whole-liver images) and 100 µm (histology). n = 4 cre− and Alb-cre+ with MK4; n = 5 Alb-cre+ with vehicle. j, Heat map showing relative amounts of oxidized phospholipids in the liver collected seven days after TAM injection. Data are mean ± s.d. of n = 3 (a–d,i). Log-rank test (h); one-way ANOVA with Dunnett’s test (i).Source data As iron-dependent lipid peroxidation is the hallmark of ferroptosis, we evaluated the levels of lipid peroxidation by performing high-resolution liquid chromatography–mass spectrometry (LC–MS)-based epilipidomics analysis, staining cells with BODIPY 581/591 C11 and Liperfluo, and determining malondialdehyde concentrations (Fig. 1e,f and Extended Data Fig. 2a–c). These studies showed that all three forms of vitamin K efficiently suppressed lipid peroxidation, and through a mechanism independent of any iron-chelating effect (Extended Data Fig. 2d), clearly prevented the RSL3-induced formation of oxidized lipid species, of which the most prominent were long-chain oxidized phosphatidylethanolamine and phosphatidylethanolamine plasmalogens (Fig. 1e and Extended Data Fig. 2a). These data demonstrate that the vitamin K family of compounds acts as potent anti-ferroptotic agents. VITAMIN K PROTECTS TISSUES FROM FERROPTOSIS We then tested whether vitamin K can also prevent ferroptosis in vivo using mice with genetic deletion of Gpx4 and pathological models, in which ferroptosis results in tissue injury. We focused on MK4 as it was the most efficacious derivative (Fig. 1a,c and Extended Data Fig. 1b). First, we treated mice with TAM-inducible deletion of Gpx4 in hepatocytes (referred